Koninklijke Philips N.V ( PHG ) united with Indica Labs, Inc. to assist oncology researchers in their cancer treatment research. The collaboration will bring together Philips' Digital Pathology Solution and Indica Labs' HALO image analysis platform, which will aid researchers in the advanced examination of certain therapy and offer personalized cancer treatments.
With the combined efforts of Philips and Indica Labs, Oncology researchers will be able to apply intelligent algorithms to digitized pathology slides and enhance their ability to gather information from tissue samples.
With cancer being one of the deadliest causes of death in the U.S, we believe Philips' latest endeavor is a major step in exploring data mining prospects and saving millions of lives. The company's research customers with a flexible investigational toolset and software features, can now analyze various cases like Ki-67 and HER2. Apart from this, Philips is providing an option to use Indica's HALO along with its Digital Pathology Solution for research purposes only.
In an effort to further assist researchers and contribute towards the advancement of healthcare technology, Philips disclosed an initiative along with the Massachusetts Institute of Technology on a separate development. The company will offer access to over 100,000 critical care patients' data, collected via its Philips Hospital to Home program, to help healthcare researchers enhance their knowledge and speed up the discovery of new treatment methods. MIT Institute for Medical Engineering's Laboratory of Computational Physiology will serve as a research hub.
Philips currently carries a Zacks Rank #4 (Sell). Investors interested in the Electronic Products-Miscellaneous industry can have a look at better-ranked stocks like GrafTech International Ltd. ( GTI ), Mistras Group, Inc. ( MG ) and VOXX International Corporation ( VOXX ). All stocks carry a Zacks Rank #2 (Buy).